

PRESS RELEASE

Change in number of shares and votes in Camurus

Lund, Sweden — 30 September 2024 — During September 2024, a total of 171,850 employee stock options in Camurus' employee stock options program ESOP 2021/2024 have been exercised for subscription of the corresponding number of shares.

As a result of the exercises made under ESOP 2021/2024, the number of shares and votes has increased by 171,850.

Prior to the exercise, the total number of shares in Camurus amounted to 58,636,918 corresponding to 58,636,918 votes. As of 30 September 2024, the total number of shares in Camurus amounts to 58,808,768, corresponding to 58,808,768 votes.

For more information

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7:00 am CEST on 30 September 2024.